AU6174500A - Microencapsulated nitric oxide synthase source - Google Patents
Microencapsulated nitric oxide synthase source Download PDFInfo
- Publication number
- AU6174500A AU6174500A AU61745/00A AU6174500A AU6174500A AU 6174500 A AU6174500 A AU 6174500A AU 61745/00 A AU61745/00 A AU 61745/00A AU 6174500 A AU6174500 A AU 6174500A AU 6174500 A AU6174500 A AU 6174500A
- Authority
- AU
- Australia
- Prior art keywords
- microcapsules
- cells
- nos
- ecdysone
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102000008299 Nitric Oxide Synthase Human genes 0.000 title claims description 61
- 108010021487 Nitric Oxide Synthase Proteins 0.000 title claims description 61
- 239000003094 microcapsule Substances 0.000 claims description 163
- 239000004098 Tetracycline Substances 0.000 claims description 63
- 229960002180 tetracycline Drugs 0.000 claims description 63
- 229930101283 tetracycline Natural products 0.000 claims description 63
- 235000019364 tetracycline Nutrition 0.000 claims description 63
- 150000003522 tetracyclines Chemical class 0.000 claims description 63
- UPEZCKBFRMILAV-JNEQICEOSA-N Ecdysone Natural products O=C1[C@H]2[C@@](C)([C@@H]3C([C@@]4(O)[C@@](C)([C@H]([C@H]([C@@H](O)CCC(O)(C)C)C)CC4)CC3)=C1)C[C@H](O)[C@H](O)C2 UPEZCKBFRMILAV-JNEQICEOSA-N 0.000 claims description 49
- UPEZCKBFRMILAV-UHFFFAOYSA-N alpha-Ecdysone Natural products C1C(O)C(O)CC2(C)C(CCC3(C(C(C(O)CCC(C)(C)O)C)CCC33O)C)C3=CC(=O)C21 UPEZCKBFRMILAV-UHFFFAOYSA-N 0.000 claims description 49
- UPEZCKBFRMILAV-JMZLNJERSA-N ecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@H]([C@H](O)CCC(C)(C)O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 UPEZCKBFRMILAV-JMZLNJERSA-N 0.000 claims description 49
- 108091026890 Coding region Proteins 0.000 claims description 39
- 229920000615 alginic acid Polymers 0.000 claims description 35
- 229940072056 alginate Drugs 0.000 claims description 28
- 235000010443 alginic acid Nutrition 0.000 claims description 28
- 108010057988 ecdysone receptor Proteins 0.000 claims description 27
- 239000013598 vector Substances 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 26
- 238000004519 manufacturing process Methods 0.000 claims description 24
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 22
- 102000040430 polynucleotide Human genes 0.000 claims description 16
- 108091033319 polynucleotide Proteins 0.000 claims description 16
- 239000002157 polynucleotide Substances 0.000 claims description 16
- 230000002950 deficient Effects 0.000 claims description 15
- 101001124991 Homo sapiens Nitric oxide synthase, inducible Proteins 0.000 claims description 14
- 241001465754 Metazoa Species 0.000 claims description 10
- 102000034527 Retinoid X Receptors Human genes 0.000 claims description 8
- 108010038912 Retinoid X Receptors Proteins 0.000 claims description 8
- 108010034634 Repressor Proteins Proteins 0.000 claims description 6
- 102000009661 Repressor Proteins Human genes 0.000 claims description 6
- 239000000833 heterodimer Substances 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 5
- 101000974009 Homo sapiens Nitric oxide synthase, brain Proteins 0.000 claims description 4
- 101001124309 Homo sapiens Nitric oxide synthase, endothelial Proteins 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 108020003175 receptors Proteins 0.000 claims description 3
- 102000005962 receptors Human genes 0.000 claims description 3
- 229920000936 Agarose Polymers 0.000 claims 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 1
- 229940102838 methylmethacrylate Drugs 0.000 claims 1
- 229920002627 poly(phosphazenes) Polymers 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 203
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 116
- 101150061166 tetR gene Proteins 0.000 description 35
- LQGNCUXDDPRDJH-UHFFFAOYSA-N 3'-GMP Natural products C1C(O)C(O)CC2(C)C(C(O)CC3(C(C(C)(O)C(O)CCC(C)C)CCC33O)C)C3=CC(=O)C21 LQGNCUXDDPRDJH-UHFFFAOYSA-N 0.000 description 29
- LRJUYAVTHIEHAI-UHFFFAOYSA-N Muristeron A Natural products C1C(O)C(O)CC2(C)C(C(O)CC3(C(C(C)(O)C(O)CCC(C)C)CCC33O)C)C3=CC(=O)C21O LRJUYAVTHIEHAI-UHFFFAOYSA-N 0.000 description 29
- LRJUYAVTHIEHAI-LHBNDURVSA-N Muristerone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H]([C@H](O)C[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)C)CC[C@]33O)C)C3=CC(=O)[C@@]21O LRJUYAVTHIEHAI-LHBNDURVSA-N 0.000 description 29
- 239000013612 plasmid Substances 0.000 description 25
- 239000000243 solution Substances 0.000 description 25
- 108090000623 proteins and genes Proteins 0.000 description 24
- 239000000463 material Substances 0.000 description 23
- 230000014509 gene expression Effects 0.000 description 21
- 239000000126 substance Substances 0.000 description 19
- 239000002299 complementary DNA Substances 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 13
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 13
- 239000000499 gel Substances 0.000 description 12
- 102000055708 human NOS2 Human genes 0.000 description 12
- 230000004044 response Effects 0.000 description 11
- 238000006467 substitution reaction Methods 0.000 description 11
- 239000000725 suspension Substances 0.000 description 11
- PJYYBCXMCWDUAZ-JJJZTNILSA-N 2,3,14,20,22-pentahydroxy-(2β,3β,5β,22R)-Cholest-7-en-6-one Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 PJYYBCXMCWDUAZ-JJJZTNILSA-N 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 10
- PJYYBCXMCWDUAZ-YKDQUOQBSA-N Ponasterone A Natural products O=C1[C@H]2[C@@](C)([C@@H]3C([C@@]4(O)[C@@](C)([C@H]([C@@](O)([C@@H](O)CCC(C)C)C)CC4)CC3)=C1)C[C@H](O)[C@H](O)C2 PJYYBCXMCWDUAZ-YKDQUOQBSA-N 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 10
- 229920001184 polypeptide Polymers 0.000 description 10
- 108090000765 processed proteins & peptides Proteins 0.000 description 10
- 102000004196 processed proteins & peptides Human genes 0.000 description 10
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 238000005538 encapsulation Methods 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 239000012091 fetal bovine serum Substances 0.000 description 9
- 230000006698 induction Effects 0.000 description 9
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 9
- 230000001105 regulatory effect Effects 0.000 description 9
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 8
- 238000006595 Griess deamination reaction Methods 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 7
- 150000001413 amino acids Chemical group 0.000 description 7
- 239000011575 calcium Substances 0.000 description 7
- 239000006285 cell suspension Substances 0.000 description 7
- 238000012217 deletion Methods 0.000 description 7
- 230000037430 deletion Effects 0.000 description 7
- 238000009792 diffusion process Methods 0.000 description 7
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
- 210000005260 human cell Anatomy 0.000 description 7
- 238000002513 implantation Methods 0.000 description 7
- 210000002540 macrophage Anatomy 0.000 description 7
- 210000004962 mammalian cell Anatomy 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- -1 peroxynitrite anion Chemical class 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 239000008159 sesame oil Substances 0.000 description 7
- 235000011803 sesame oil Nutrition 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 235000001014 amino acid Nutrition 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 230000004888 barrier function Effects 0.000 description 6
- 210000004379 membrane Anatomy 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 241000701022 Cytomegalovirus Species 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- 241000238631 Hexapoda Species 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 238000000636 Northern blotting Methods 0.000 description 5
- 108010084455 Zeocin Proteins 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 150000001768 cations Chemical class 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 208000029742 colonic neoplasm Diseases 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 238000011068 loading method Methods 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 206010009944 Colon cancer Diseases 0.000 description 4
- 206010033128 Ovarian cancer Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 239000000710 homodimer Substances 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 239000003270 steroid hormone Substances 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 229920001169 thermoplastic Polymers 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 229910002651 NO3 Inorganic materials 0.000 description 3
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 3
- 102000006538 Nitric Oxide Synthase Type I Human genes 0.000 description 3
- 108010008858 Nitric Oxide Synthase Type I Proteins 0.000 description 3
- 102000008052 Nitric Oxide Synthase Type III Human genes 0.000 description 3
- 108010075520 Nitric Oxide Synthase Type III Proteins 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 235000013681 dietary sucrose Nutrition 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000009931 harmful effect Effects 0.000 description 3
- 102000055707 human NOS1 Human genes 0.000 description 3
- 102000055702 human NOS3 Human genes 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000011580 nude mouse model Methods 0.000 description 3
- 229920002239 polyacrylonitrile Polymers 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 229960004793 sucrose Drugs 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 238000012384 transportation and delivery Methods 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- ZIIQCSMRQKCOCT-UHFFFAOYSA-N 2-acetamido-3-methyl-3-nitrososulfanylbutanoic acid Chemical compound CC(=O)NC(C(O)=O)C(C)(C)SN=O ZIIQCSMRQKCOCT-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 241000255601 Drosophila melanogaster Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 101150005851 NOS gene Proteins 0.000 description 2
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 2
- 208000012868 Overgrowth Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 108010039918 Polylysine Chemical group 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 241000714474 Rous sarcoma virus Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 102000004243 Tubulin Human genes 0.000 description 2
- 108090000704 Tubulin Proteins 0.000 description 2
- 102000018594 Tumour necrosis factor Human genes 0.000 description 2
- 108050007852 Tumour necrosis factor Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical group C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 238000002399 angioplasty Methods 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000001461 cytolytic effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- XEYBHCRIKKKOSS-UHFFFAOYSA-N disodium;azanylidyneoxidanium;iron(2+);pentacyanide Chemical compound [Na+].[Na+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].[O+]#N XEYBHCRIKKKOSS-UHFFFAOYSA-N 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 229960003722 doxycycline Drugs 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 238000001952 enzyme assay Methods 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 230000003176 fibrotic effect Effects 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 229920000656 polylysine Chemical group 0.000 description 2
- 239000004926 polymethyl methacrylate Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000001698 pyrogenic effect Effects 0.000 description 2
- 208000037803 restenosis Diseases 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 235000015424 sodium Nutrition 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 229940083618 sodium nitroprusside Drugs 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 230000005909 tumor killing Effects 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- ODKSFYDXXFIFQN-FXLFCPKBSA-N (2S)-2-amino-5-(diaminomethylideneamino)(214C)pentanoic acid Chemical compound N[14C@@H](CCCNC(N)=N)C(=O)O ODKSFYDXXFIFQN-FXLFCPKBSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- VGGGPCQERPFHOB-MCIONIFRSA-N Bestatin Chemical compound CC(C)C[C@H](C(O)=O)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1 VGGGPCQERPFHOB-MCIONIFRSA-N 0.000 description 1
- VGGGPCQERPFHOB-UHFFFAOYSA-N Bestatin Natural products CC(C)CC(C(O)=O)NC(=O)C(O)C(N)CC1=CC=CC=C1 VGGGPCQERPFHOB-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101000658545 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) Type I restriction enyme HindI endonuclease subunit Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 101150109636 Inos gene Proteins 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- IAJILQKETJEXLJ-SQOUGZDYSA-N L-guluronic acid Chemical compound O=C[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O IAJILQKETJEXLJ-SQOUGZDYSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004695 Polyether sulfone Substances 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 229920002367 Polyisobutene Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000009833 antibody interaction Effects 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- AEMOLEFTQBMNLQ-UHFFFAOYSA-N beta-D-galactopyranuronic acid Natural products OC1OC(C(O)=O)C(O)C(O)C1O AEMOLEFTQBMNLQ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 229930189065 blasticidin Natural products 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229920001727 cellulose butyrate Polymers 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 201000010897 colon adenocarcinoma Diseases 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- AEMOLEFTQBMNLQ-YBSDWZGDSA-N d-mannuronic acid Chemical compound O[C@@H]1O[C@@H](C(O)=O)[C@H](O)[C@@H](O)[C@H]1O AEMOLEFTQBMNLQ-YBSDWZGDSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical class CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 150000002058 ecdysones Chemical class 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 229940027941 immunoglobulin g Drugs 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 239000000201 insect hormone Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 239000011229 interlayer Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000012633 leachable Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 229920005684 linear copolymer Polymers 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000029052 metamorphosis Effects 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 238000013392 nude mouse xenograft model Methods 0.000 description 1
- 235000021048 nutrient requirements Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000009894 physiological stress Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 229920006393 polyether sulfone Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001007 puffing effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 108020003113 steroid hormone receptors Proteins 0.000 description 1
- 102000005969 steroid hormone receptors Human genes 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000004416 thermosoftening plastic Substances 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 229950009811 ubenimex Drugs 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/126—Immunoprotecting barriers, e.g. jackets, diffusion chambers
- A61K2035/128—Immunoprotecting barriers, e.g. jackets, diffusion chambers capsules, e.g. microcapsules
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Obesity (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Manufacturing Of Micro-Capsules (AREA)
Description
WO 01/09342 PCT/GB00/02924 -1 MICROENCAPSULATED NITRIC OXIDE SYNTHASE SOURCE Field of the Invention This invention relates to microencapsulated recombinant cells for in vivo 5 delivery of therapeutic substances. Background to the Invention Experiments have demonstrated that nitric oxide (NO) can have beneficial effects in a number of disease states. However, NO can be a double edged sword: the 10 high levels of NO produced by macrophages and endothelial cells can have a tumor killing effect, whereas low and medium doses of NO may actually promote tumor growth, upregulation of p53 and tumor angiogenesis. Control of NO levels in vivo, however, is difficult to achieve. A well established pharmacological NO-based therapeutic approach is to add 15 NO in some form. One way to do this is simply to add authentic NO solution. However, this approach is problematical, as pure NO solution is very unstable in aqueous media. An alternative and widely used approach is to use NO-donors, which can release NO continuously in a biological environment. Compounds such as glycerin 20 trinitrate (GTN), sodium nitroprusside (SNP) and S-nitroso-N-acetyl-DL penicillamine (SNAP) are widely used therapeutically. However, a problem with all classical NO donors is that NO release is often not linear. Furthermore NO-donors may also give rise to related NO species that have different biological properties from native NO. For example, NO may react with oxygen derived radicals to 25 produce toxic substances such as the peroxynitrite anion (ONOO-). Recent attempts to overcome the problems associated with NO donors have focussed on the use of targeted gene delivery approaches. For example, vessel walls transfected with an iNOS cDNA following angioplasty show reduced restenosis. This method is, however, limited in that it may be difficult to regulate expression of 30 the iNOS from such cells and it is difficult to transfect all the cells in a specific target region.
WO 01/09342 PCT/GB00/02924 -2 Summary of the Invention We have produced human cell lines that can express one of the three known human nitric oxide synthases, inducible nitric oxide synthase (iNOS), neuronal nitric oxide synthase (nNOS) and endothelial nitric oxide synthase (eNOS), in the presence 5 of the insect steroid hormone ecdysone or an analog thereof. We have also produced a cell line that can express human iNOS in the presence of tetracycline or an analog thereof Thus, we have produced cell lines which are capable of producing NO in a dose- and time-dependent manner by treatment of the cells with ecdysone or an 10 analog thereof or tetracycline or an analog thereof Our cell-based NO "switches" produce biologically active inducible NOS capable of generating NO. Furthermore, we have encapsulated a cell line, which expresses iNOS under the control of an ecdysone-responsive promoter, in immunoisolating microcapsules. We have shown that under in vitro culture conditions, the cells can survive for longer 15 than one month. Furthermore. the encapsulated cells could be induced to produce NO at a controlled level upon stimulation by muristerone A. When muristerone A was removed, the NO levels fell. Cells could be "switched on" again by the reapplication if muristerone A. When microencapsulated cells of the invention were implanted into mice, 20 they survived and upon removal from the host mice were still capable of induction by muristerone A and of NO production. We have now shown, in a nude mouse xenograft model that the microencapsulated cells have the ability to slow down tumor growth and even to completely inhibit tumor growth. This remarkable result opens up a completely new 25 strategy for cancer therapy. Thus, microencapsulated cells of the invention may be used as artificial endothelial cells or as artificial macrophage cells in the treatment of human conditions related to abnormal NO metabolism or conditions where the administration of nitric oxide is required. This approach has advantages over NO 30 donor and gene therapy approaches as 100% of the cells introduced into a target region will be capable of generating NO in a highly regulated way.
WO 01/09342 PCT/GB00/02924 -3 According to the present invention there is thus provided microcapsules suitable for administration to a human or animal which microcapsules harbour cells containing a polynucleotide construct, said construct comprising: (a) a promoter which is responsive to ecdysone or an analog thereof and 5 which is operably linked to a coding sequence for a nitric oxide synthase (NOS) or a functional variant thereof; or (b) a promoter operably linked to one or more tetracycline operator site sequences and a coding sequence in that order, wherein the coding sequence encodes a nitric oxide synthase (NOS) or a functional 10 variant thereof The invention also provides: - microcapsules of the invention for use in a method of treatment of the human or animal body; 15 - use of microcapsules of the invention for the manufacture of a medicament for use in the treatment of a condition associated with deficient NO production; - a pharmaceutical composition comprising microcapsules of the invention and a pharmaceutically acceptable carrier or diluent; 20 - a method of delivering microcapsules to a host comprising administering microcapsules of the invention to the host; - a method of treating a host suffering from a condition associated with deficient NO production, which method comprises administering ecdysone or an analog thereof to a host which harbours microcapsules of the invention. 25 - a product containing microcapsules of the invention and ecdysone or an analog thereof as a combined preparation for simultaneous, separate or sequential use in the treatment of condition associated with deficient NO production; - a polynucleotide construct comprising: 30 (a) a promoter operably linked to a coding sequence, wherein the promoter is responsive to ecdysone or an analog thereof and the WO 01/09342 PCT/GB00/02924 -4 coding sequence encodes a nitric oxide synthase (NOS) or a functional variant thereof; or (b) a promoter operably linked to one or more tetracycline operator site sequences and a coding sequence in that order, wherein the coding 5 sequence encodes a nitric oxide synthase (NOS) or a functional variant thereof; - a vector which incorporates a polynucleotide construct of the invention; - a process for preparing microcapsules comprising encapsulating cells of the invention. 10 Brief description of the Drawings Figure 1(a) shows the plasmid map for pIND-hiNOS-f (human iNOS); Figure 1(b) shows the plasmid map for pIND-hnNOS-f (human nNOS); and Figure 1 (c) shows the plasmid map for p-IND-heNOS-f (human eNOS). Figure 1(d) shows the 15 plasmid map of pTet-hiNOS-f (human iNOS). Figure 2(a) shows generation of NO by EcR293 clone 11, following treatment with muristerone A. EcR293 clone 11 cells were grown with varying concentrations of muristerone A and at different time intervals supernatants were taken and the 20 Griess reaction was used to measure the nitrite concentration. Figure 2(b) shows Northern and Western blots of carried out on extracts from cells treated with either I pM or 10LM muristerone A. Extracts were also taken from cells grown in the absence of muristerone A. For Northern blots, filters were probed with a human iNOS cDNA and hybridisation with human P-actin was used as a loading control. 25 For Western blots, filters were probed with a polyclonal antibody raised against the 7 C-terminal residues of human iNOS: Cyc-Arg-Nle-Orn- (Ser-Leu-Glu-Met-Ser-Ala Leu). The filters were subsequently stripped and re-probed with an anti-human a tubulin antibody as a loading control. 30 Figure 3 shows generation of NO in a panel of cell lines transfected with pTet-hiNOS-f Cells were treated with 1 pg/ml tetracycline for 24h and NOS activity WO 01/09342 PCT/GB00/02924 -5 was assessed by assaying for accumulated nitrite using the Griess reaction. Figure 4 shows the general strategy used for microencapsulation of cells. In step 1, EcR293 clone 11 cells are mixed with Naalginate in the barrel of a syringe. 5 In step 2, the resulting solution is expelled dropwise through the syringe needle into a solution of CaC1 2 giving rise to polymer beads containing EcR293 clone 11 cells. In step 3, the microencapsuled are hardened by mixing with poly-L-lysine. In step 4, the microcapsules are ready for in vitro culture or in vivo injection/transplantation. Alternatively, microcapsules may be stored in DMEM medium supplemented with 10 10% fetal bovine serum. Figure 5 shows generation of NO by encapsulated EcR293 clone 11 cells, following treatment with muristerone A. EcR293 clone 11 cells were encapsulated with alginate-poly-L-lysine-alginate. Cells were induced to produce NO at a 15 controlled level by the application of 10pM muristerone A. When muristerone A was removed the production of NO fell. On re-application of 104M muristerone A the level of NO production again increased. Figure 6 shows the results of experiments carried out with microencapsulated 20 EcR293 clone 11 cells. (A) shows the results of subcutaneous injection of human colon cancer DLD-1 cells (1x 106 per mouse) with microencapsulated human EcR293 clone 11 cells (5x 106 per mouse) either under induction conditions (ponasterone A 1mg per mouse, c) or sesame-seed oil only (*). Each point represents mean±S.D. for 5 mice. 25 Detailed Description of the Invention Constructs. Vectors and Cells Steroid hormones are small hydrophobic molecules that can diffuse through 30 the plasma membrane of cells where they can bind reversibly to specific steroid hormone-receptor proteins in the cytoplasm or nucleus. The binding of hormone WO 01/09342 PCT/GB00/02924 -6 activates the receptor, enabling it to bind with high affinity to specific DNA sequences that act as transcriptional enhancers. This binding increases the level of transcription from certain nearby genes. A pulse of the insect steroid hormone ecdysone triggers metamorphosis in 5 Drosophila melanogaster, showing effects such as chromosomal puffing within minutes of hormone addition. Mediating this response is the functional ecdysone receptor, which is a heterodimer of the ecdysone receptor (EcR) and the product of the ultraspiracle gene (USP). Insect hormone responsiveness can be recreated in cultured mammalian cells 10 by cotransfection of a cell with a functional ecdysone receptor (a heterodimer of EcR and USP) and an ecdysone responsive construct and treatment of the cell with ecdysone or an analog thereof A tetracycline responsive system can be created in cultured mammalian cells by cotransfection of a cell with a plasmid encoding a tetracycline repressor protein 15 (tetR) and a plasmid containing a tetracycline responsive element linked to a promoter. The promoter sequence is used to drive heterologous gene expression. The tetracycline responsive element comprises particular DNA sequences called tetracycline operator sites, which can bind a homodimer of tetR. If those sequences are positioned between a promoter and a coding sequence in a construct, the presence 20 of tetR bound to a tetracycline operator site will prevent the promoter driving expression of the coding sequence. However, when tetracycline is added to cells the tetracycline binds to tetR homodimers leading to a conformational change in tetR, such that it is unable to bind a tetracycline operator site. The tetR:tetracycline complex dissociates from the Tet operator site and allows the promoter to drive 25 expression of the coding sequence. (i) Constructs The invention provides polynucleotide constructs which are responsive to ecdysone or an analog thereof. The invention also provides polynucleotide 30 constructs which are responsive to tetracycline or an analog thereof The ecdysonse responsive constructs comprise a promoter operably linked to WO 01/09342 PCT/GB00/02924 -7 a coding sequence, wherein the promoter is responsive to ecdysone or an analog thereof and the coding sequence codes for a NOS or a functional variant or fragment thereof The tetracycline responsive constructs comprise a promoter operably linked 5 to one or more teracycline operator site sequences and a coding sequence in that order, wherein the coding sequence codes for a NOS or a functional variant or fragment thereof. The constructs may comprise DNA or RNA. They may also include within them synthetic or modified nucleotides. A number of different types of modification 10 to polynucleotides are known in the art. These include methylphosphonate and phosphorothioate backbones, addition of acridine or polylysine chains at the 3' and/or 5' ends of the molecule. For the purposes of the invention, it is to be understood that the constructs described herein may be modified by any method available in the art. Such modifications may be carried out in order to enhance the in vivo activity or 15 lifespan of constructs of the invention. Constructs of the invention may be produced recombinantly, synthetically, or by any means available to those of skill in the art. The term "operably linked" refers to a juxtaposition wherein the components described are in a relationship permitting them to function in their intended manner. Thus, a regulatory sequence, such as a promoter, "operably linked" to a coding 20 sequence is positioned in such a way that expression of the coding sequence is achieved under conditions compatible with the regulatory sequence. A promoter for use in an ecdysone-reponsive construct of the invention may be any promoter which can drive the transcription of a coding sequence to which it is operably linked in the presence of the steroid hormone ecdysone or an analog thereof. 25 The promoter may be a naturally occurring promoter from a Drosophila melanogaster or other insect ecdysone-responsive gene. Alternatively, the promoter may be a non-naturally occuring promoter. A non-naturally occuring promoter may be used which comprises a minimal promoter and an ecdysone-responsive element (EcRE). An EcRE is a nucleotide sequence to which a functional ecdysone receptor 30 can bind in the presence of ecdysone. Suitable minimal promoters include the minimal heat shock promoter.
WO 01/09342 PCT/GB00/02924 -8 An ecdysone-responsive promoter may comprise more than one EcRE, for example 2 to 10 elements or more preferably 4 to 6 elements. The sequence of an EcRE will depend on the exact functional ecdysone receptor used. If a modified functional ecdysone receptor is used (see below) it may be appropriate to use a 5 modified EcRE (see No et al., Proc. Natl. Acad. Sci. USA, 93: 3346-3351). The EcRE(s) and minimal promoter sequences do not have to be immediately adjacent. Because EcREs function as transcriptional enhancers, they can be placed some distance upstream, for example from 1, 10 or 25 nucleotides to 30, 40, 50, 100, 500 or 1000kb upstream of a minimal promoter. EcREs could even be placed further 10 than 1kb upstream of a minimal promoter. Generally, if multiple copes of an EcRE are used, the mutiple copies will be arranged in an array, one after the other. Constructs of the invention may be responsive to ecdysone [(2f, 3f, 5f, 22R) 2.3,14,22,25-pentahydroxycholest-7-en-6-one] or an analog thereof Suitable analogs of ecdysone for use in the invention include muristerone A [203, 3 ,5a, 1 1a, 15 14, 20, 22-heptahydroxy-5p3, 7-cholesten-6-one] or ponasterone A [ (2fl, 3f, 5f#, 22R) 2, 3, 14, 20, 22, 25-pentahydroxycholest-7-en-6-one] and GSn-E (Invitrogen, San Diego, CA; see also Dhadialla et al., 1998, Ann. Rev. Entomol. 43: 545-569). A promoter for use in an tetracycline-reponsive construct of the invention may be any promoter which can drive the transcription of a coding sequence to 20 which it is operably linked in the presence of the antibiotic tetracycline or an analog thereof. Generally, the choice of promoter will depend on the host cell to be used for expression of the coding sequence. Typically, expression in mammalian cells, for example human cells will be required and thus a mammlian promoter will be 25 preferred. Mammalian promoters, such as 1-actin promoters, may be used. Tissue specific promoters may be used. Viral promoters may also be used, for example the Moloney murine leukaemia virus long terminal repeat (MMLV LTR), the rous sarcoma virus (RSV) LTR promoter, the SV40 promoter, the human cytomegalovirus (CMV) IE promoter, adenovirus, HSV promoters (such as the HSV IE promoters), or 30 HPV promoters, particularly the HPV upstream regulatory region (URR). Viral promoters are readily available in the art. Constitutive promoters, for example the WO 01/09342 PCT/GB00/02924 -9 CMV promoter, are preferred. Tetracycline-responsive constructs comprise one or more tetracycline operator site (TetO 2 ) sequences, situated between the promoter and coding sequence. For example, two, three, four or even up to ten TetO 2 sequences may be used. 5 Typically, if more than one TetO 2 site is used those sites will be arranged in the form of an array. However, other intervening nucleotide sequences may be situated between individual TetO, sites. For example one, two, three, four, five, up to ten or up to 15 nucleotides may intervene between any two TetO 2 sites. The TetO, sequence is 5'-TCCCTATCAGTGATAGAGA-3' (Hillen and 10 Berens, 1994, Annu. Rev. Microbiol. 48, 345-369; Hillen et al., 1983, J. Mol. Biol. 169, 707-721) or a functional variant thereof The TetO 2 sequence or a functional variant thereof is capable of being bound by a homodimer of tetR or a functional variant thereof. A functional variant of the TetO 2 sequence is a sequence which is similar to 15 that of the TetO 2 sequence and which remains capable of binding a homodimer of tetR or a functional variant thereof. The affinity of tetR for the TetO 2 sequence is K, = 2xl 0 1 1
M
- (as measured under physiological conditions), where KB is the binding constant (Hillen and Berens, 1994, supra). The binding affinity of tetR for a functional variant of the TetO 2 sequence may be substantially the same as that of tetR 20 for the TetO 2 sequence. Alternatively, tetR may have a binding affinity for a functional variant of the TetO 2 sequence which is greater or less than that of tetR for the TetO 2 sequence. For example, the affinity of tetR for a functional variant of the TetO, sequence may be from KB = 2x10 9
M
1 to 2x10 1 3
M-
1 or more preferably from 2x10 1 M to 2x10 2
M
1 . 25 A functional variant of TetO 2 typically comprises a sequence substantially similar to that of the TetO 2 sequence. Thus, a functional variant of TetO, will generally have at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 98% or at least 99% sequence identity to the TetO 2 sequence, calculated over the full length of those sequences. 30 A functional variant of the TetO 2 sequence may be a modified version of that sequence obtained by, for example, nucleotide substitution or deletion. Up to 1, up WO 01/09342 PCT/GB00/02924 -10 to 2, up to 3, up to 4, up to 5, up to 6 or more nucleotide substitutions or deletions or combinations thereof may be made to the TetO, sequence to produce a functional variant of that sequence. Constructs of the invention may be responsive to the antibiotic tetracycline or 5 an analog thereof Tetracycline binds to tetR homodimers, such that the tetR:tetracylcine complex dissociates from the TetO 2 sequence. The association constant of tetracycline to tetR is 3 x 109 M 1 . Preferred analogs of tetracycline will have an association constant substantially similar to or greater than that of tetracycline for tetR. Suitable analogs of tetracycline include doxycycline. 10 Doxycycline exhibits similar dose response and induction characteristics with constructs of the invention, but has a longer half-life than tetracycline (48 hours vs. 24 hours respectively). The coding sequence used in both ecdysone- and tetracycline-responsive contructs of the invention can be any sequence which encodes a NOS or a functional 15 variant thereof The phrase "nitric oxide synthase" is intended to include all naturally occuring forms of iNOS, nNOS and eNOS as well as variants which retain NOS activity, for example variants produced by mutagenesis techniques. Preferably the coding sequence encodes a NOS of mammlian origin for example rodent (including rat and mouse) or human. Most preferably the coding sequence encode the human 20 iNOS (GenBank accession number: X73029, Coding sequence 226-3687), human nNOS (GenBank accession number: U17327, Coding sequence 686-4990) or human eNOS (GenBank accession number: M95296, Coding sequence 21-3632) or a functional variant of any one of those enzymes. A functional variant of a NOS is any polypeptide which demonstrates NOS 25 activity, for example a fragment of a NOS. A coding sequence which codes for a functional variant of a NOS may be, for example a fragment of a full length NOS coding sequence. A fragment may be of any length, so long as the polypeptide for which it codes has NOS activity. A functional variant of a NOS typically comprises a sequence substantially 30 similar to that of the naturally occurring form of the relevant NOS sequence. Thus, a functional variant of a NOS will generally have at least 60%, at least 70%, at least WO 01/09342 PCT/GB00/02924 -11 80%, at least 90%, at least 95%, at least 98% or at least 99% sequence identity to the relevant NOS sequence, calculated over the full length of those sequences. Thus, the coding sequence may be modified by nucleotide substitutions or deletions. For example up to 1, 2 or 3 to 10, 25, 50, 75 or 100 substitutions or 5 deletions or combinations thereof may be made to produce a functional variant of a NOS. A polynucleotide encoding a NOS may alternatively or additionally be modified by one or more insertions and/or deletions and/or by an extension at either or both ends. The modified polynucleotide generally encodes for a polypeptide which has NOS activity. Degenerate substitutions may be made and/or substitutions 10 may be made which would result in a conservative amino acid substitution when the modified sequence is translated, for example as shown in the Table below. Amino acids in the same block in the second column and preferably in the same line in the third column may be substituted for each other. 15 ALIPHATIC Non-polar G A P ILV Polar-uncharged C S T M NQ Polar-charged D E KR AROMATIC HF W Y Sequence identity may be calculated as follows. The UWGCG Package provides the BESTFIT program which can be used to calculate identity (for example 20 used on its default settings) (Devereux et al (1984) Nucleic Acids Research 12, p387 395). The PILEUP and BLAST algorithms can be used to calculate identity or line up sequences (typically on their default settings), for example as described in Altschul S. F. (1993) J Mol Evol 36:290-300; Altschul, S, F et al (1990) J Mol Biol 215:403-10. Software for performing BLAST analyses is publicly available through 25 the National Centre for Biotechnology Information (http://www.ncbi.nlm.nih.gov/).
WO 01/09342 PCT/GB00/02924 -12 (ii) Vectors Both types of construct of the invention can be incorporated into a recombinant replicable vector. The vector may be used to replicate the construct in a compatible host cell. A vector may also provide for expression of the NOS coding 5 sequence when the vector is harboured by an appropriate host cell. The vectors may be for example, plasmid, virus or phage vectors provided with an origin of replication and optionally a regulator of the ecdysone-responsive promoter or promoter used in a tetracycline-responsive construct. The vectors may contain one or more selectable marker genes, for example an 10 ampicillin resistance gene for selection in bacterial cells or a G418 or a zeocin resistance gene for selection in mammalian cells. Vectors of the invention may also comprise so-called "suicide genes", for example the herpes simplex virus thymidine kinase gene (HSV-tk). The HSK-tk gene may be induced in the presence of a small molecule such as ganciclovir, 15 resulting in the elimination of a cell harbouring the HSV-tk gene. Alternatively, a cell which harbours a vector of the invention which does not comprises the HSK-tk gene may be provided with the HSV-tk gene by integration of the HSV gene into the host cell genome or by transfection or transformation of the cell with a further vector comprising the HSV-tk gene. 20 (iii) Cells Vectors of the invention, which incorporate an ecdysone-inducible construct, may be introduced into a suitable host cell by any appropriate transformation or transfection technique. 25 Preferably, the host cell will permit the expression of the NOS coding sequence. Thus, the cells may be chosen to be compatible with the said vector and may be for example bacterial, yeast, insect or mammalian cells. For NOS gene expression to be induced in the presence of ecdysone or an analog thereof, a cell harbouring an ecdysone inducible construct must preferably also be capable of 30 expressing a functional ecdysone receptor. As described above, the wild type Drosophila functional ecdysone receptor is WO 01/09342 PCT/GBOO/02924 -13 a heterodimer of the ecdysone receptor (EcR) and the product of the ultraspiracle gene (USP). Thus cells of the invention may be capable of expressing EcR and USP. However, replacement of EcR's natural heterodimeric partner USP with its mammlian homologue retinoid X receptor gives a heterodimer which can give more 5 potent induction of an ecdysone responsive promoter. Thus cells of the invention may be capable of expressing EcR and RXR. It will be clear that cells of the invention may be capable of expressing functional variants of either subunit of the heterodimer. Functional variants of EcR and USP/RXR are polypeptides which can heterodimerise with their partner and can, when heterodimerised, allow ecdysone 10 responsive dimerisation to occur. In some cases functional variants may bind to non wild type EcREs. Examples of functional variants and modified EcREs are described in No et al. Proc. Natl. Acad. Sci. USA, 93: 3346-3351. Preferred cells for use in the invention are human cells. Particularly preferred cells are EcR293 cells (Invitrogen, San Diego, CA; Catalogue No: R650-07; EcR293 15 is a derivative of the human fetal kidney cell line HEK293 (ECACC accession number 85/20602)). EcR293 cells are particularly suitable as they stably transformed with the vector pVgRXR. That vector is capable of expressing a functional variant of EcR, VgEcR, and RXR in mammalian cells and thus allows the expression of a functional ecdysone receptor. Other suitable cell lines include EcR-CHO and EcR 20 3T3 (Invitrogen, San Diego, CA; Cat. Nos: R660-07 and R680-07 respectively). Those two cell lines are stably transformed with the same vector, pVgRXR, as the EcR293 cell line. Vectors of the invention, which incorporate an tetracycline-inducible construct, may be introduced into a suitable host cell by any appropriate 25 transformation or transfection technique. Preferably, the host cell will permit the expression of the NOS coding sequence in the presence of tetracycline or an analog thereof. Thus, the cells may be chosen to be compatible with the said vector and may be for example bacterial, yeast, insect or mammalian cells. For NOS gene expression to be regulated such that 30 expression does not occur in the absence of tetracycline, a cell harbouring a tetracycline-inducible construct must preferably also be capable ofexpressing the WO 01/09342 PCT/GB00/02924 -14 tetracycline repressor protein (tetR) or a functional variant thereof. A functional variant of tetR is a polypeptide which is similar to tetR and which remains capable of binding, as a homodimer, the TetO, site or a functional variant thereof and tetracycline or an analog thereof. Typically, the binding affinity 5 of a functional variant sequence of tetR for the TetO 2 site or a functional variant thereof or tetracycline or an analog thereof may be substantially the same as the binding affinity of the tetR polypeptide for the TetO 2 site or a functional variant thereof or tetracycline or an analog thereof. Alternatively, a functional variant sequence may have a binding affinity which may be greater or less than that of the 10 tetR polypetide. The TetR gene encodes a repressor protein of 207 amino acids with a calculated molecular weight of 23 kDa (Hillen and Berens, 1994, supra). A functional variant of tetR typically comprises an amino acid sequence substantially similar to that of the tetR sequence. Thus, a functional variant of a tetR will 15 generally have at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 98% or at least 99% sequence identity to tetR, calculated over the full length of those sequences. The calculation of sequence identities is described above. A functional variant of the tetR sequence may be a modified version of that sequence obtained by, for example, amino acid substitution or deletion. Up to 1, up 20 to 10, up to 20, up to 50, up to 75, up to 100 or more amino acid substitutions or deletions or combinations thereof may be made to the tetR sequence to produce a functional variant of that sequence. Substitutions are preferably made which result in a conservative amino acid substitution, for example as shown in the Table above. Preferred cells for use in the invention are human cells. Particularly preferred 25 cells are T-REx cells (Invitrogen, San Diego, CA; Catalogue Nos: R710-07, R712 07, R714-07 and R716-07). T-Rex cells are particularly suitable as they stably transformed with the plasmid pcDNA6/TR which generates high level expression of the tetR polypeptide. However, any cell line can be used which expresses tetR or a functional variant thereof. 30 WO 01/09342 PCT/GB00/02924 -15 Microcapsules Cells of the invention may be encapsulated to give microcapsules. Preferably, microcapsules of the invention will be suitable for administration to a human or animal. Typically, microcapsules which are suitable for administration to a 5 human or animal are biocompatible, immunoisolatory and mechanically stable. Biocompatible microcapsules do not elicit a host response sufficient to result in rejection of the microcapsules or to render the microcapsules non-functioning. The term host responses includes all responses by a host to heterologous material, including for example immune responses such as cytotoxic and systemic responses, 10 fibrotic responses, foreign body responses and other types of inflammatory responses induced by heterologous material. Biocompatibility may be determined by a combination of factors, including for example, the microcapsule material, surface texture and shape. Materials used to form the microcapsules are thus typically selected for their 15 ability to be accepted by a host harbouring the microcapsules. Suitable materials should generally be stable under in vivo physiological conditions and stresses. Typically, suitable materials will be stable in vivo over extended periods of time, for example up to 2 months, up to six months, up to 1 year or up to 2 years. Suitable materials should also preferably be free from or have a content of 20 leachable pyrogenic substances or other harmful, irritating or immunogenic substances. If the material to be used to form microcapsules is not free of those substances, it may be purified to remove the unwanted substances. Preferred materials include reversibly and irreversibly gellable substances (for example, those that form hydrogels) and water-insoluble thermoplastic polymers. 25 Suitable hydrogel forming materials include alginates. Alginate is a linear copolymer composed of two monomeric units, D-mannuronic acid and L-guluronic acid. Preferred alginates are those low in or free from toxic substances, pyrogens and immunogenic materials such as proteins and complex carbohydrates, for example highly purified high-G alginates. 30 Alginates may be induced to form gels in the presence of certain divalent cations, for example Ca". The major limitation to the use of Ca' alginate as a WO 01/09342 PCT/GB00/02924 -16 microcapsule material is its sensitivity to chelating compounds such as phosphate, citrate and lactate or anti-gelling cations such as Mg> or Na 2 . To overcome this limitation alginate gels can be stabilized by replacing Ca2+ with other divalent cations having a higher affinity for alginate. The affinity series for various divalent caitons 5 is, in order of decreasing affinity for alginate: Pb> Cu 2 + > Cd 2 > > Ba2+> Sr" > Ca 2 > Co 2 = Ni 2+ = Zn2+> Mn 2 . It has been shown that the rigidity of alginate gels in general increases with the affinity (though Cd 2 + and Ni 2 do not fit this rule): Pb 2 > Cu 2 = Ba > Sr > Cd > Ca
'
- > Ni 2 > Zn 2+ > Co 2 > Ni. However, the high toxicity of most of these ions, in particular Pb", Cu 2 and Cd 2 -, means that use for 10 microcapsules suitable for administration to a human or animal is strictly limited. In pratise only Sr 2 and Ba 2- are likely to be suitable for encapsulation of living cells. Alginate gels may also be stabilized by adding other multivalent ions such as Ti' and A13. Alginate forms strong complexes with polycations such as chitosan or 15 polypeptides, or synthetic polymers such as polyethylenimine. These complexes do not dissolve in the presence of Ca' chelators or anti-gelling cations and may therefore optionally be used both to stabilize the gel and to reduce the porosity. Additionally, covalent crosslinking may be used to stabilize alginate gels. Covalent crosslinking may be carried out by techniques such as direct crosslinking of the 20 carboxyl groups and covalent grafting of alginate with synthetic polymers. This gives gels with improved stability and mechanical strength. However, these techniques involve reactive chemicals and thus may be difficult to apply to the encapsulation of living cells. Suitable thermoplastics are typically those which are mildly hydrophobic, for 25 example those having a solubility parameter of from 8 to 15 (joules/m 3 )Y or more preferably from 6 to 14 (joules/m 3
)
w [Solubility parameter as defined in Polymer Handbook 3 rd Ed., John Wiley and Sons, NY]. Suitable polymers are selected to have a solubility parameter low enough so that they are soluble in organic solvents, but high enough so that they may partition to from a membrane. Such polymers 30 should be free from labile nucleophilic moieties and be resistant to oxidants and enzymes even, for example, in the absence of stabilizing agents.
WO 01/09342 PCT/GB00/02924 -17 Examples of suitable thermoplastic polymers are polyacylonitrile vinyl chloride (PAN/PVC), polyacrylonitrile (PAN), polymethylmethacrylate (PMMA), polyvinyldifuoride (PVDF), polyethylene oxide, polyolefins (eg. polyisobutylene or polypropylene), polysulfones or cellulose derivatives (eg. cellulose acetate or 5 cellulose butyrate). The microcapsule forming material may also comprise one or more substance which reduces or eliminates local host inflammatory responses to the microcapsules and/or stimulates the formation of a suitable environment for the microcapsules. For example, an antibody to a mediator of the immune response could be included. 10 Suitable antibodies include antibodies to the lymphokines, tumour necrosis factor (TNF) and interferon (IFN). An anti-inflammatory steroid may be included in the microcapsule forming material. Also, a substance which stimulates angiogenesis (ingrowth of capillary beds) can be included. This may be desirable where the isolated cells or tissues are required to be in close contact with the host bloodstream 15 for proper functioning. Cells which are encapsulated may themselves be capable of generating any of the substances mentioned in this paragraph. The texture of the exterior of the microcapsules is typically formed so after implantation it provides an optimal interface with the tissues of the host. The appropriate texture will in part be determined by the site of implantation. For 20 example, if the microcapsules are to be introduced into the intraperitoneal cavity of the host, its surface should be smooth. A smooth surface may discourage excessive overgrowth by fibroblasts. The overgrowth of fibroblasts may be disadvantageous as it may result in the deposition of a poorly permeable basement membrane around microcapsules and consequent isolation of microcapsules from the host. However, if 25 the microcapsules are to be embedded in the soft tissues of the host the surface may be moderately rough or stippled. A factor to be taken into account is whether it is desired for host cells to attach to the surface of the microcapsules or alternatively if such contact is to be avoided. Microcapsules of any shape may be formed. However, certain microcapsule 30 shapes may elicit fibrotic responses and therefore those shapes are typically avoided. Thus microcapsules preferably should not comprises structures having interlayers WO 01/09342 PCT/GB00/02924 -18 such as brush surfaces or folds. In general, opposing microcapsule surfaces or edges either from the same or adjacent microcapsules should be at least 2mm apart, more preferably at least 5mm apart. Preferred shapes for microcapsules are thus, substantially spherical, substantially cylindrical, U-shaped cylinders and flat sheets 5 or sandwiches. Substantially spherical microcapsules may be formed and offer the advantage that delivery of cells so encapsulated may be carried out by intraperitoneal injection. This may be advantageous if systemic delivery is required. Cylinders, by contrast, generally require surgical implantation, but as described below, may have advantages in terms of surface area to volume ratios. 10 Microcapsules of the invention are typically immunoisolatory. Immunoisolatory microcapsules protect encapsulated cells from the host immune system. The encapsulating material may protect encapsulated cells by: (1) substantially preventing or minimising components of the host foreign body response mechanisms from entering a microcapsule; (2) providing a barrier which 15 substantially prevents or minimises contact between the encapsulated cells and components of the host immune system; and (3) providing a barrier which substantially prevents or minimises contact between inflammatory. antigenic or other harmful substances that may be present in a microcapsule and components of the host foreign body response mechanisms. 20 Thus the microcapsule material will generally allow passage of substances up to a predetermined size, but prevent the passage of larger substances and therefore microcapsules are differentially permeable. The molecular weight cutoff (MWCO) selected for particular microcapsules may be determined in part by (1) the type and extent of immunological rejection anticipated after introduction of microcapsules to 25 the host; and (2) the molecular size of the largest substance whose passage into and out of the microcapsules is required. The type and extent of immunological rejection encountered by microcapsules may depend in part on the type of genotype of the encapsulated cells and the genotype of the host. When the encapsulated cells are allogenic to the host 30 rejection may proceed largely through cell-mediated attack by the host's immune cells against the implanted cells. When the encapsulated cells are xenogenic to the WO 01/09342 PCT/GB00/02924 -19 recipient, rejection through assembly of the host's cytolytic complement attack complex may predominate, as well as antibody interaction with complement. The MWCO of the encapsulation material must therefore be sufficiently low to prevent access of the molecules required to carry out the above mentioned 5 rejection mechanisms to the encapsulated cells, yet sufficiently high to allow passage of any therapeutic substance produced by the encapsulated cells. For example, materials can be used which allow passage of molecules up to about the size of Clq (-400kd), the largest polypeptide required for the assembly of the cytolytic complement attack complex. Alternatively, it is possible to use microcapsule 10 materials which allow passage of molecules up to the size of immunoglobulin G (-150kd) and exclude larger molecules. Preferably, microcapsules of the invention may have a low MWCO. NO is a small molecule and thus microcapsules of the invention can have a low MWCO, which will in turn increase immunoisolation of the encapsulated cells. 15 Diffusion of small molecules appears unaffected by alginate gels, whereas passage of larger molecules may be restricted. The highest diffusion rates of proteins, indicating the most open pore structure, are found in beads made from high G alginates. Several procedures for stabilizing alginate gels also influence porosity. For example, the formation of poly-anion-polycation membranes with polypeptides 20 or chitosan can be used to prevent diffusion of antibodies from microcapsules. By controlling the molecular weight of the polycations, pore sizes below selected cut-off values can be obtained. An example of a suitable polycation is poly-L-lysine; the lower the molecular weight M,, of the poly-L-lysine, the less permeable the capsules. Contact between components of the host response mechanisms and 25 encapsulated cells and other inflammatory, antigenic or other harmful substances may be substantially prevented or minimised of the microcapsule material forms a physical barrier between those substances. The thickness of the barrier may vary, but typically it should be sufficiently thick to prevent direct contact between substances on either side of the barrier. Thus the thickness of the barrier generally ranges from 5 30 to 200gm, preferably from 10 to 100pm and most preferably from 20 to 50pgm. Microcapsules of the invention may harbour from 1 to at least 100 cells, at WO 01/09342 PCT/GBOO/02924 -20 least 200 cells, at least 500 cells, at least 1000 cells or at least 1 x 10' cells, up to 1 x 104 cells or up to 1 x 10' cells. Factors which influence the number of cells that a microcapsule may harbour include: (1) microcapsule size and shape; (2) mitotic activity within the microcapsule; and (3) viscocity of the interior of the microcapsule. 5 In relation to the first of these factors, microcapsule size and shape, the diffusion of nutrients into cells and of waste products out of cells is critical to the continued viability of the encapsulated cells. Since diffusion in and out of the microcapsule may be limited by the microcapsule surface area, the surface to volume ratio of microcapsules will be critical in determining how many cells may be 10 maintained within the microcapsules. Among the nutrient requirements of encapsulated cells is that of oxygen. The oxygen requirement of cells must be determined for any cell type of choice. However, a typical example may be that for cells encapsulated in a cylindrical microcapsule of 900gm outer diameter implanted in the intraperitoneal space (pO2 15 45-50mmHg) the optimal total cell volume is in the range of up to 20%, preferably 1 to 15% and most preferably about 5% of the microcapsule volume. For a cylindrical microcapsule of 400gm outer diameter the optimal cell volume may be from 30 to 65% total microcapsule volume and preferably may be 35%. At implantation sites where the partial oxygen pressure is less than the 20 peritoneum, lower loading densities may be required. Implantation into an artery (pO2 - 95mmHg), by contrast, will allow support of a greater cell volume per microcapsule. If the cells used actively divide in the microcapsule, then they will continue to divide until they fill the available space, or until phenomena such as contact 25 inhibition limit further division. Thus, when dividing cells are used the size and shape of the microcapsules may be chosen so that complete filling of the microcapsule will not lead to a loss of nutrient passage to cells because of diffusion limitations. Typically, microcapsules that will be filled to confluency with cells will be no more than 250gm in cross-section, such that cells in the interior will have less 30 than 15 between them and an external surface, preferably less than 120 cells and more preferably less than 5 cells.
WO 01/09342 PCT/GB00/02924 -21 Cells present in densities of up to 70% of the microcapsule volume can be viable, but cell solutions in this concentration range would have considerable viscosity. Thus formation of microcapsules with such high cell densities may be difficult. Generally, cell densities of 30% or less, or 20% or less will be appropriate 5 for microcapsule formation. Microcapsules are preferably substantially spherical or substantially cylindrical. They may be of any appropriate size, but the size will be influenced by a number of factors including some of those mentioned above. For example, nutrient diffusion may limit microcapsule size. Substantially spherical microcapsules may be 10 for example from 0.01 to 4.0 mm, preferably from 0.1 to 3.0 mm and more preferably from 0.2 to 2.0 mm in diameter. Substantially cylindrical microcapsules may be from 0.01 to 4.0 mm, preferably from 0.1 to 3.0 mm and more preferably from 0.2 to 2.0 mm in outer diameter. Such cylindrical microcapsules may be for example from 0.1 mm, 0.2 or 0.5 mm in length to for example 5 mm, 10 mm or 20 15 mm in length. For a population of microcapsules, the above dimensions may be average dimensions for the population. Microcapsule formation Microcapsules may be produced according to methods well known to those 20 skilled in the art. Alginate microcapsules may be formed, for example, by mixing an alginate solution with a cell suspension and then dripping the alginate-cell suspension into a solution containing Ca 2 " ions. A poly-L-lysine layer may be added by to the microcapsules thus formed by incubation in a solution of poly-L-lysine. The poly-L 25 lysine layer may increase mechanical stability and decrease permeability of the resulting microcapsules. A final alginate layer may be added by a further incubation in an alginate solution. Typically an initial sodium alginate solution at a concentration of from 1.5 to 12%, more preferably from 2 to 4% is prepared by dissolving an appropriate amount 30 of Na+-alginate in distilled water or buffer. The suspension may be stirred for 6 hours by a magnetic stirrer or left overnight on a rotary shaker at room temperature.
WO 01/09342 PCT/GB00/02924 -22 The resulting suspension may be filter sterilized by use of a 0.22ptm membrane filter. Cells may then be mixed with the Na -alginate solution. If the cells are added as a suspension in a buffer, the presence of phosphate, citrate, EDTA and divalent cations should be avoided. Microcapsules may formed by dripping the alginate-cell 5 suspension (from a syringe with an inner diameter of for example from 0.22 to 1.0mm, at a distance of for example about 20cm away from the CaCl 2 surface) into a solution containing for example from 20 to 100mM Ca 2 + ions. The size of the microcapsules may be controlled by the application of a coaxial airstream. For a given Na -alginate solution (concentration, type and intrinsic viscosity) the size of 10 the microcapsules depends only on the airflow for a given syringe diameter and microcapsules of diameters in the range of, for example, from 0.2mm to 3mm may be produced. The microcapsules may be left to harden in the CaCl 2 for from 5 to 30 minutes, depending on their diameter. The resulting microcapsules may be washed in saline or a suitable buffer and 15 then suspended in a solution of poly-L-lysine. The poly-L-lysine used may be a molecular weight of for example from 24, 000 to 65, 000, preferably 27, 000 and the microcapsules may typically be suspended in a 0.05% (w/v) solution of poly-L lysine. After another washing step with saline or a suitable buffer, the microcapsules may be suspended in a Na-alginate solution (at a concentration of for example, 20 0.15%). The microcapsules may further be suspended in a solution of sodium citrate (at a concentration of for example, 55mM). The microcapsules are generally given a further saline wash before use. Cylindrical microcapsules can be formed by loading thermoplastic polymer hollow fibres, such as polyethersulfone hollow fibers, with a cell suspension and 25 sealing the ends of the hollow fibre. Newly-formed microcapsules may be maintained until use under sterile conditions in a non-pyrogenic, serum-free defined nutrient medium or balanced salt solution at about 37 0 C until implantation. Alternatively the microcapsules may be cryopreserved. 30 Therapeutic Use WO 01/09342 PCT/GB00/02924 -23 Microcapsules of the invention may be used to treat conditions which are associated with deficient NO production. Microcapsules may also be used for the manufacture of a medicament for use in the treatment of a condition associated with deficient NO production. Conditions associated with deficient NO production 5 include those that may be a result of abnormal deficient NO production and also those that although not a result of abnormal deficient NO production as such, may be treated by raising NO levels. The condition of a patient suffering from such an infection can be improved by administration of an inhibitor. A therapeutically effective amount of an inhibitor may be given to a human patient in need thereof 10 Microcapsules of the invention may therefore be used to treat, for example, hyperlipidaemia, renal failure, hypertension, restenosis after angioplasty, atherscloerosis and its complications, complications of heart failure or schizophrenia. NO is known to play an important role in the host defence against tumors. Rodent macrophages activated by IFN-y and IFN-a produce large quantities of NO, 15 which has been shown to kill certain tumor cells, including human ovarian cancer, leukaemic, colon cancer and prostate cancer cells. By contrast, human macrophages produce a much lower level of NO and have probably have a limited tumor killing ability. Therefore, microcapsules of the invention may be used as artificial macrophages in the treatment of cancers. 20 Microcapsules may be administered to a human or animal in need thereof and ecdysone or an analog thereof administered subsequently. Alternatively, ecdysone or an analog thereof may be administered at the same time as the microcapsules. Thus the invention provides a product containing microcapsules of the invention and ecdysone or an analog thereof as a combined preparation for simultaneous, separate 25 or sequential use in the treatment of a condition associated with deficient NO production. Implantation of microcapsules is typically performed under sterile conditions. Generally, the microcapsules are implanted at a site in the host which (1) allows for appropriate delivery of NO produced by the microcapsules to the host; and (2) allows 30 for passage of nutrients to the encapsulated cells. Also the site may be chosen to allow for the recapture of the microcapsules.
WO 01/09342 PCT/GB00/02924 -24 Microcapsules may be administered in a variety of dosage forms. Thus, they can be administered orally, for example as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules. The inhibitors may also be administered parenterally, either subcutaneously, intravenously, intramuscularly, 5 intrasternally, transdermally or by infusion techniques. The microcapsules may also be administered as suppositories. A physician will be able to determine the required route of administration for each particular patient. The formulation of microcapsules for use in preventing or treating a condition associated with deficient NO production will depend upon factors such as the nature 10 of the microcapsules, whether a pharmaceutical or veterinary use is intended, etc. Microcapsules are typically formulated for administration in the present invention with a pharmaceutically acceptable carrier or diluent. The pharmaceutical carrier or diluent may be, for example, an isotonic solution. For example, solid oral forms may contain, together with the microcapsules, diluents, e.g. lactose, dextrose, 15 saccharose, cellulose, corn starch or potato starch; lubricants, e.g. silica, talc, stearic acid, magnesium or calcium stearate, and/or polyethylene glycols; binding agents; e.g. starches, arabic gums, gelatin, methylcellulose, carboxymethylcellulose or polyvinyl pyrrolidone; disaggregating agents, e.g. starch, alginic acid, alginates or sodium starch glycolate; effervescing mixtures; dyestuffs; sweeteners; wetting 20 agents, such as lecithin, polysorbates, laurylsulphates; and, in general, non-toxic and pharmacologically inactive substances used in pharmaceutical formulations. Such pharmaceutical preparations may be manufactured in known manner, for example, by means of mixing, granulating, tabletting, sugar-coating, or film coating processes. Liquid dispersions for oral administration may be syrups, emulsions and 25 suspensions. The syrups may contain as carriers, for example, saccharose or saccharose with glycerine and/or mannitol and/or sorbitol. Suspensions may contain as a carrier, for example a natural gum, agar, sodium alginte, pectin, methylcellulose, carboxymethylcellulose, or polyvinyl alcohol. The suspensions or solutions for intramuscular or intratumor injections may 30 contain, together with the microcapsules, a pharmaceutically acceptable carrier, e.g. sterile water, olive oil, sesame oil, ethyl oleate, glycols, e.g. propylene glycol, and if WO 01/09342 PCT/GB00/02924 -25 desired, a suitable amount of lidocaine hydrochloride. Solutions for intravenous administration or infusions may contain as carrier, for example, sterile water or preferably they may be in the form of sterile, aqueous, isotonic saline solutions. 5 A therapeutically effective amount of microcapsules is administered to a patient. The dose of microcapsules may be determined according to various parameters, especially according to the microcapsules used; the age. weight and condition of the patient to be treated; the route of administration; the required regimen; and the condition to be treated. Again, a physician will be able to 10 determine the required route of administration and dosage for any particular patient. A typical dose is from about 1mg/kg to 10mg/kg of body weight, according to the activity of the microcapsules, the age, weight and conditions of the subject to be treated, the type and severity of the degeneration of the microcapsules and the frequency and route of administration. 15 Ecdysone or an analog thereof or tetracycline or an analog thereof may be administered simultaneously, separately or sequentially with microcapsules of the invention. Ecdysone or an analog thereof or tetracycline may be administered and formulated for administration, for example as described above for microcapsules of the invention. The amount of ecdysone or tetracycline required and the frequency of 20 admininstration will depend on similar considerations as apply to microcapsule dosages. It may be necessary to give several doses of ecdysone or tetracycline over a period of time or alternatively, it may only be necessary to administer a single dose at the beginning of the treatment. Ecdysone or an analog thereof or tetracycline or an analog thereof can itself 25 be microencapsulated, for example by a method for microencapsulation as described above. Such microcapsules could be administered along with microcapsules of the invention. Thus, the invention provides a product containing microcapsules of the invention and microcapsules harbouring ecdysone or an analog thereof or tetracycline or an analog thereof as a combined preparation for simultaneous, separate or 30 sequential use in the treatment of a condition associated with deficient NO production. Ecdysone or tetracycline may also be incorporated info the material used WO 01/09342 PCT/GB00/02924 -26 to encapsulate cells of the invention. Encapsulation of ecdysone or an analog thereof or tetracycline or an analog thereof or incorporation of ecdysone or tetracycline into the encapsulation material may abrogate the need for more than one administration of ecdysone or an analog thereof or tetracycline or an analog thereof. 5 The following Examples illustrates the invention: Examples Materials and methods 10 Unless indicated otherwise, the methods used are standard biochemical techniques. Examples of suitable general methodology textbooks include Sambrook et al., Molecular Cloning, a Laboratory Manual (1989) and Ausubel et al., Current Protocols in Molecular Biology (1995), John Wiley & Sons, Inc. 15 Subculture Procedure All of the operations were carried out under strict aseptic conditions in a laminar flow hood. The medium was removed from near-confluent flasks and gently washed twice with serum-free DMEM (Dulbecco's Modified Eagle's Medium). A trypsin/versene mix was added to the cells and they were incubated for 5-10 min. 20 until the cells had detached. Once the cells had detached they were resuspended in pre-warmed (37 C) serum-free DMEM and then pelleted by centrifugation at 1 0 00rpm for 5min. It was essential to wash the cells to remove the residue of the tyrpsin/versene (serum-free DMEM was used for washing). The supernatant was removed and the cells gently resuspended in 15ml of 90% DMEM with glutamine, 25 10% fetal bovine serum (FBS, cell culture grade) that had been pre-warmed to 37 0 C. The cells were then transferred to three or four T-25 flasks (or equivalent) and placed in a humidified, 37' C, 5% CO 2 incubator. It typically took 3-4 days for cell cultures to reach 80-90% confluency. Media were changed 2 times a week and cells subcultured at a ratio of 1:3 to 1:4 when they reached 80-90% confluency. Cells 30 were subcultured when approaching confluency to avoid the accumulation of floating and dead cells. Cells were frozen for storage in 95% FBS and 5% DMSO.
WO 01/09342 PCT/GB00/02924 -27 Induction using Muristerone A Cells could be maintained in non selection medium for 2-3 weeks without losing inducibility following muristerone A treatment. Non-selection medium was used by choice, although selection medium worked equally well. Cells were seeded 5 at 1-2 x 10 5 /ml concentration for 12 well or 96 well plates. Semi-confluent or confluent plates or flasks were used for induction. Figure 1(a) shows overnight induction in 12 well plates (3-30 hours) following the addition of different doses of muristerone A. Nitrate concentrations are measured using the Griess Reaction (see below). 10 Western blot analysis Cells were pelleted at 200g, followed by two washes in ice-cold PBS, pH 7.2, then resuspended in the extraction buffer (50mM NaF, 20mM Hepes (pH 7.8), 450mM NaCI, 25% (vol/vol) glycerol, 0.2mM EDTA, 0.5mM dithiothreitol, 0.5mM 15 phenylmethylsulfonyl fluoride, leupeptin (0.5tg/ml), protease inhibitor (0.5pg/ml), trypsin inhibitor (1.0 ig/ml), aprotinin (0.5 ig/ml), bestatin (40pig/ml)) and left on ice for 10 min. Following centrifugation at 10,000g for 10 min at 4°C, the supernatant was collected and the cell extract assayed for protein using the BCA kit (Pierce). One fifth of a volume of five times sample buffer (0.25M Tris-HCL (pH6.8), 0.4M 20 DTT, 5% SDS, 0.5% bromophenol blue, 50% glycerol) was added to each sample and boiled for 5 min prior to storage at -70 0 C. Electrophoresis was carried out on 6% SDS polyacrylamide gels with 25gg samples. Proteins were transferred to polyvinylidine difluride (PVDF) membranes (Amersham) and immunoblotting carried out with the appropriate antibody using ECL (Amersham). Where necessary, 25 blots were stripped in 62.5mM Tris-HCL 100mM j3-mercaptoethanol/ 2% SDS, (pH 6.7) and reprobed with different antibodies. Northern Blotting Poly(A) +-- mRNA was isolated using a micro-fastrack mRNA purification kit 30 (Invitrogen), separated by electrophoresis and transferred onto Hybond N membrane (Amersham). Phosphoimaging (BAS 1000, Fujix) was used to quantify the signals WO 01/09342 PCT/GB00/02924 -28 using the MacBas image analysis software. NOS activity assay Griess Reaction (Green et al., 1982, Analysis of nitrate, nitrite and ['IN] 5 nitrate in biological fluids, Anal. Chem. 126, 131-138): NOS activity was determined for both intact cells and their lysates. For intact cells, 100pl of the culture medium was mixed with 100gl of Griess reagent (1:1 mixture of 1% sulfanilamide in 5%
H
3 P0 4 and 0.1% naphthylethyethylenediamine dihydrochloride in water) for 10 min at room temperature and the absorbance at 543 nm was recorded. A serial dilution of 10 sodium nitrite was used as a standard. For enzyme assays on cell lysates, 100pg of lysate was mixed with 100pl reaction reagent from the NOS detect system (Stratagene NOS detect kit, Cat. No. 204500). The kit measures the conversion of [ 14 C]arginine to [ 4 C] citrulline, and is specific for the NOS pathway. 15 Example 1 - Generation of NOS transfected cell lines under the control of an ecdysone-responsive or a tetracycline-responsive promoter Three plasmids were generated, each of which expressed one of the human NOS isoforms under the control of an ecdysone-responsive promoter. An additional 20 plasmid was constructed placing the iNOS cDNA under the control of a tetracycline regulated promoter. (I) pIND-hiNOS-f (Figure 1 a) 4164bp of the human iNOS cDNA (GenBank accession number: X73029, 25 Coding sequence 226-3687) was cut from its original vector (Bluescript KS) using the restriction endonucleases, KpnI and Spel and cloned into pIND (Invitrogen, San Diego, CA; Catalogue No: V705-20) which had been cut with KpnI and XbaI. The resulting plasmid was sequenced to confirm that the cDNA had inserted in the correct orientation. 30 (II) plND-hnNOS-f (Figure lb) WO 01/09342 PCT/GB00/02924 -29 5kb of the human nNOS cDNA (GenBank accession number: U 17327, Coding sequence 686-4990) was cut from its original vector (Bluescript KS) using the restriction endonucleases, XbaI and KpnI and cloned into pIND (Invitrogen, San Diego, CA; Catalogue No: V705-20) which had been cut with NheI and KpnI. The 5 resulting plasmid was sequenced to confirm that the cDNA had inserted in the correct orientation. (III) plND-heNOS-f (Figure 1c) The wild type human eNOS (GenBank accession number: M95296, Coding 10 sequence 21-3632) was cut from its original vector (Bluescript KS) using the restriction endonucleases, HindIII and NotI and cloned into pIND (Invitrogen, San Diego, CA; Catalogue No: V705-20) which had been cut with HindI and NotI. The resulting plasmid was sequenced to confirm that the cDNA had inserted in the correct orientation. 15 (IV) pTet-hiNOS-f (Figure 1 d) The human iNOS cDNA (GenBank accession number: X73029, Coding sequence 226-3687) was cut from its original vector (Bluescript KS) using the restriction endonucleases, KpnI and SpeI and cloned into pcDNA4/TO (Invitrogen, 20 San Diego, CA) which had been cut with KpnI and XbaI. The resulting plasmid was sequenced to confirm that the cDNA had inserted in the correct orientation. The pIND plasmid contains 5 modified EcREs called E/GREs which bind a modified functional ecdysone receptor. That modified functional ecdysone receptor 25 can be expressed by another plasmid, pVgRXR (Invitrogen, San Diego, CA; Catalogue Number: V730-20). pVgRXR constitutively expresses a heterodimeric receptor comprising a modified ecdysone receptor (VgEcR) and RXR. Thus, a cell transformed with pVgRXR and one of the three plasmids described above (I, II or Ill) will express NOS in the presence of ecdysone or an analog thereof In the 30 presence of ecdysone the functional ecdysone receptor binds to the E/GREs and transcription of the NOS cDNA is initiated.
WO 01/09342 PCT/GB00/02924 -30 The plasmid pIND-hiNOS-f was used to transfect a human fetal kidney cell line, EcR293 (Invitrogen, San Diego, CA; Catalogue No: R650-07), which is stably transformed with pVgRXR. Transfections were carried out using Superfect reagent (Qiagen) and transfectants were isolated following double selection on G418 5 (400gg/ml) and zeocin (250pg/ml) for 14 days. Thus, cells were isolated which constitutively expressed the subunits of a functional ecdysone receptor, RXR/VgEcR and the human iNOS cDNA under the control of an ecdysone-inducible promoter. 10 The T-Rex system (Invitrogen, San Diego, CA; Catalogue No: K1020-01) is a tetracycline-regulated mammalian expression system that uses regulatory elements from the E. coli Tn]0-encoded tetracycline resistance operon. The pcDNA4/TO plasmid allows expression of a gene of interest under te control of the strong human cytomegalovirus immediate-early (CMV) promoter and two tetracycline operator 2 15 (TetO 2 ) sites. The pcDNA6/TR plasmid expresses high levels of the TetR gene under the control of the human CMV promoter. Thus, a cell transformed with pcDNA6/TR and the plasmid described above (IV) will express NOS in the presence of tetracycline or an analog thereof When present, tetracycline binds to tetR which undergoes a conformational change such that it dissociates from the TetO, sites. 20 Expression of the iNOS gene is then induced, driven by the CMV promoter. The plasmid pTet-hiNOS-fwas used to transfect the cell line T-REx-293 ((Invitrogen, San Diego, CA; Catalogue No: R710-07). The T-REx-293 cell line is a human embryonic kidney 293 cell line which has been transfected with the pcDNA6/TR plasmid and thus generates high level expression of the tetracycline 25 repressor protein (TetR). Transfections were carried out using conditions as described above for the muristerone A inducible constructs. Transfectants were isolated following selection on zeocin (200pg/ml) for the human iNOS cDNA expressing plasmid and blasticidin (5tg/ml) for the tetR expressing plasmid. Thus, cells were isolated which constitutively expressed the tetracycline 30 repressor protein (tetR) and the human iNOS cDNA in the presence of tetracycline.
WO 01/09342 PCT/GB00/02924 -31 Example 2 - Isolation and characterization of ecdysone-responsive and tetracycline-responsive human cell lines (A) Isolation of a panel of ecdysone-responsive human cell lines and determination of NOS activity 5 A panel of 20 G418/zeocin-resistant clones were examined for their ability to generate NO. A total of 5 were identified that could be induced to produce NO at varing levels after treatment with 100pM muristerone A for 24 hours. NOS activity was determined in both intact cells and in cell lysates. For intact cells, the Griess reaction was used to determine the concentration of NO in 10041 of culture medium. 10 For enzyme assays, 100jg of cell lysate was mixed with 100l reaction reagent from NOS detect system (Stratagene NOS detect kit, Cat. No.204500). The kit measures the conversion of [' 4 C] arginine to [ 14 C] citrulline, and is specific for NOS. For a typical experiment, transfectants were plated out on 12 well Falcon tissue culture plates at a cell density of 1 x 10 5 /ml and nitrite was measured by the Griess reaction. 15 Muristerone A (Invitrogen) was added at a final concentration of 100gM to specific wells, and after induction for 24hr, 100p l of culture supernatant was used to measure nitrite concentration using the Griess reagent. The results are reported as the average of assays run on triplicate wells. Well-to-well variation was less than 10%. 20 (B) Time and dose response of EcR293 clone 11 cells generating NO One of the transfectants, clone 11, was selected for further study. Cells were grown with varying concentrations of muristerone A, and at different time intervals, supernatant were taken and the Griess reaction was used to measure the nitrite concentration. The results are reported as the average of assays run in triplicate. 25 Well-to-well variation was less than 10%. See Figure 2a. (i) Muristerone A-dependent expression of the human iNOS gene. Northern blot analysis was carried out with 2pg of polyA+ RNA isolated from cells which had been treated with muristerone A for 24 hr. A human iNOS cDNA probe was used to detect the presence of a 4kb band in mRNA extracted from cells treated with either 30 1 pM or 10 M muristerone A. Human 3-actin mRNA was used as a loading control. See Figure 2b.
WO 01/09342 PCT/GBOO/02924 -32 (ii) Western blot of iNOS protein expression was carried out on untreated control cells or cells treated with 1 0pM muristerone A. The cells were harvested and 20gg of whole cell extracts loaded on to a 6% polyacrylamide gel. Following electrophoresis, the proteins were transferred to a filter and probed with a polyclonal 5 antibody raised against the 7 C-terminal residues of human iNOS: Cyc-Arg-Nle-Orn (Ser-Leu-Glu-Met-Ser-Ala-Leu). Filters were stripped and an antibody against human alpha-tubulin. (Insight Biotchnology) was used as a control. See Figure 2b. (C) Isolation of a panel of tetracycline-responsive human cell lines and 10 determination of NOS activity A panel of 4 tetracycline-regulated iNOS expressing cell lines were isolated, designated clone 1, clone 2. clone 5 and clone 22. In the absence of the inducer tetracycline the iNOS transfectants were unable to express mRNA as the two Tet operator sites (Tet02) are occupied by the repressor 15 protein effectively blocking transcription. When tetracycline is added to the culture medium, it binds to the TetR protein and changes its conformation. The altered conformation of the repressor is unable to bind the operator sites, and consequently iNOS can be expressed. Nitrite concentrations were determined using the Griess reaction (see figure 3). 20 Example 3 - Encapsulation of recombinant EcR293 clone 11 cells EcR293 clone 11 cells were used for encapsulation studies. Prior to encapsulation, EcR293 clone 11 cells were maintained in Dulbecco's media supplemented with 10% fetal bovine serum (FBS) and penicillin (100 units/ml) and 25 streptomycin (100pg/ml) in the absence of both G418 and zeocin. The cells were encapsulated in alginate-poly-L-lysine-alginate microcapsules as follows: Cells were harvested with trypsin then resuspended in a 1.8% sodium alginate solution (Sigma, catalogue no. A2033, medium viscosity, filter sterilised through a 0.25pm membrane) in PBS at between 0.5-5 x 10' cells/ml. The suspension was 30 placed in a syringe and held 20 to 40cm above a beaker containing an excess (100ml) of stirred ice cold calcium chloride solution (0.2M, pH7, filter sterilized). The cell WO 01/09342 PCT/GB00/02924 -33 suspension was extruded through a 21G needle and droplets made to fall into the solution of sterile ice cold calcium chloride. Upon contact with the calcium chloride buffer, alginate gelation is immediate and the cells are encapsulated in an alginate complex. The microcapsule size was controlled by the extrusion pressure and the 5 needle gauge. A typical hypodermic needle produced beads of from 0.5 to 2mm in diameter. Other shapes could be obtained by using a mould the wall of which was permeable to calcium ions. Droplets were allowed to gel for between 1 to 30 minutes and were then suspended for 1 to 10 minutes in a 1:1 mixture of poly-L-lysine and 1.8% sodium 10 alginate solution. The positively charged polylysine forms a complex with the alginate to form a semipermeable membrane. Immediately following encapsulation and washing, the cells were maintained in Dulbecco's media (supplemented with 10% fetal bovine serum (FBS) and penicillin and streptomycin) or PBS prior to further experimentation. 15 The microencapsulation procedure is illustrated schematically in Figure 4. Example 4 - In vitro culture of the encapsulated cells When EcR293 clone 11 cells were encapsulated with immunoisolating microcapsules fabricated from alginate-poly-L-lysine-alginate, the cells survive for at 20 least 3 days. Moreover, the encapsulated cells could be induced to produce nitric oxide at a controlled level upon stimulation with muristone A at a concentration of 10pM.. When muristerone A was removed, the NO level dropped. The cells could be "switched on" again when muristerone A was reapplied at a concentration of 10pgM 25 (see Figure 5). Example 5 - In vivo injection and retrieval of the encapsulated cells Male CT-1 mice (3-4 weeks old, about 15 grams body weight), were intraperitoneally injected with 1 ml of microcapsules from Example 3 with a 16G 30 catheter. The inducer, 1mg per mouse of muristerone A, was added at the same time. Two days later, a full midline incision of the abdominal skin and a 0.75cm incision WO 01/09342 PCT/GB00/02924 -34 through the abdominal wall were made and the microcapsules were retrieved from the peritoneal cavity. The cells were washed three times with ice-cold phosphate-buffered saline (PBS) and then supplemented with Dulbecco's media. The capsules were then tested 5 for survival and inducibility by muristerone A. The test showed that the microencapsulated cells were still capable of induction by 10pM muristerone A and could produce nitric oxide accordingly. It is thus feasible that this type of microencapsulated cell line could be used as an artificial endothelial cell or macrophage for human disease treatment. 10 Example 6 - Microencapsulated cells as an artificial macrophage for treating human ovarian and colon cancer A nude mouse/xenograf model was used to assess the ability of microencapsulated cells to kill tumor cells in vivo. The present studies utilized two 15 human carcinoma cell lines that produce rapidly growing subcutaneous tumors in nude mice were used. DLD-1 is a human colon adenocarcinoma cell line, while SK OV-3 is an ovarian carcinoma cell line. Both were obtained from ATCC. The cell lines were maintained as adherent monolayers in DMEM supplemented with 10% FBS. Cultures were maintained on plastic and incubated in 5% CO 2 -95% air at 37 0 C. 20 All cultures were free of Mycoplasma. For all in vivo experiments, tumor cells in the exponential phase were harvested by a 1 to 2 min treatment with 0.25% trypsin, 0.02% EDTA solution (w/v). The flasks were tapped sharply to dislodge the cells, DMEM added, and the cell suspension pipetted to produce a single-cell suspension. The cells were washed, 25 resuspended in Ca2 /Mg2*-free PBS and diluted to the desired concentration. Cell viability was determined by trypan blue exclusion, and only single-cell suspensions of greater than 95% viability were used for in vivo experiments. To produce subcutaneous tumors in female CD1 nude mice, suspensions of tumor cells in Iml of PBS were mixed with lml of alginate encapsulated EcR293 30 clone 11 cells. To induce NO production, 10mg of ponasterone A was dissolved into lml of sesame oil. The ponasterone A solution was mixed with the tumor WO 01/09342 PCT/GB00/02924 -35 cell/encapsulated cell mixture. In control experiments lml of sesame oil was used in the absence of ponasterone A. A total volume of 300gl of the cell suspension/mixture was injected (with a 21G needle) subcutaneously into the lateral flank proximal to the midline of the 5 unanaesthetized animal. Each experiment used between 5 and 10 animals. The mean diameter of the tumors was determined by measuring tumor length (1) and width (w) by calipers. Tumor volume was estimated by using the formula-tumor volume = length x width 2 x 2.54. Tumors obtained from each of the experiments were either frozen in liquid nitrogen or subsequent analysis by northern or western blotting or for 10 histological evaluation. The above procedure was carried out with both of the human carcinoma lines. Colon cancer DLD-1 cells (lxl 06 per mouse) were injected subcutaneously along with microencapsulated EcR293 clone 11 cells; 5x1 06 cells microencapsulated as described in Example 3 above. The microencapsulated cells were injected in the 15 presence of either sesame oil alone or sesame oil and ponasterone A (1mg per mouse). The results are shown in Figure 6a and demonstrate that the microencapsulated cells plus ponasterone A treatment slowed the growth of DLD-1 cells considerably compared to the treatment of microencapsulated cells alone. The experiment was repeated with SK-OV-3 ovarian cancer cells. 20 Encapsulated EcR293 clone 11 cells, 3x10 6 cells per mouse microencapsulated as described in Example 3 above, were introduced into mice with 5 x 10' SK-OV-3 cells. The encapsulated cells were introduced in either in the presence of sesame oil alone or sesame oil containing ponasterone A (1mg per mouse). The results are shown in Figure 6b and demonstrate that the microencapsulated cells plus 25 ponasterone A treatment completely inhibited the growth of SK-OV-3 cells. SK OV-3 cells showed considerable growth in the absence of ponasterone A. 30
Claims (26)
1. Microcapsules suitable for administration to a human or animal which microcapsules harbour cells containing a polynucleotide construct, said construct 5 comprising: (a) a promoter which is responsive to ecdysone or an analog thereof and which is operably linked to a coding sequence for a nitric oxide synthase (NOS) or a functional variant thereof; or (b) a promoter operably linked to one or more tetracycline operator site 10 sequences and a coding sequence in that order, wherein the coding sequence encodes a nitric oxide synthase (NOS) or a functional variant thereof
2. Microcapsules according to claim 1, wherein the construct is 15 incorporated into a vector.
3. Microcapsules according to any one of the preceding claims, wherein the microcapsules comprise at least one of alginate, acrylic, hydroxyethyl methyacrylate-methyl-methacrylate, polyphosphazene or agarose. 20
4. Microcapsules according to any one of the preceding claims, wherein the microcapsules contain an average of from 1 to 1 x 10' cells.
5. Microcapsules according to any one of the preceding claims, which 25 are the microcapsules are substantially spherical microcapsules or substantially cylindrical microcapsules.
6. Microcapsules according to claim 5 which are substantially spherical microcapsules having an average diameter of from 0.01 to 4.0 mm. 30
7. Microcapsules according to claim 5 which are cylindrical WO 01/09342 PCT/GB00/02924 -37 microcapsules having an average length of from 0.1 to 20 mm and an average outer diameter of from 0.1 to 4.0 mm
8. Microcapsules according to any one of the preceding claims for use in 5 a method or treatment of the human or animal body by therapy.
9. Microcapsules according to claim 8 for use in the treatment of a condition associated with deficient NO production.
10 10. Use of microcapsules according to any one of claims 1 to 7 in the manufacture of a medicament for use in the treatment of a condition associated with deficient NO production.
11. A pharmaceutical composition comprising microcapsules according to 15 any one of claims 1 to 7 and a pharmaceutically acceptable carrier or diluent.
12. A method of delivering microcapsules to a host comprising administering microcapsules according to any one of claims 1 to 7. 20
13. A method of treating a host suffering from a condition associated with deficient NO production, which method comprises administering ecdysone or an analog thereof to a host which harbours microcapsules as defined in any one of claims 1 to 7. 25
14. A product containing microcapsules according to any one of claims 1 to 7 and ecdysone or an analog thereof as a combined preparation for simultaneous, separate or sequential use in the treatment of a condition associated with deficient NO production. 30
15. A polynucleotide construct comprising: (a) a promoter operably linked to a coding sequence, wherein the WO 01/09342 PCT/GB00/02924 -38 promoter is responsive to ecdysone or an analog thereof and the coding sequence encodes a nitric oxide synthase (NOS) or a functional variant thereof; or (b) a promoter operably linked to one or more tetracycline operator site 5 sequences and a coding sequence in that order, wherein the coding sequence encodes a nitric oxide synthase (NOS) or a functional variant thereof
16. A polynucleotide construct according to claim 15, wherein the NOS is 10 human inducible NOS.
17. A polynucleotide construct according to claim 15, wherein the NOS is human neuronal NOS. 15
18. A polynucleotide construct according to claim 15, wherein the NOS is human endothelial NOS.
19. A polynucleotide construct according to any one of claims 15 to 18, wherein the promoter in part (a) comprises a minimal promoter and an element or 20 elements which is/are responsive to ecdysone or an analog thereof.
20. A polynucletoide construct according to any one of claims 15 to 18, wherein two operator site sequences are present in part (b). 25
21. A vector which incorporates a polynucleotide construct as defined in any one of claims 15 to 20.
22. A cell which harbours a polynucleotide construct according to any one of claims 15 to 20 or a vector according to claim 21. 30
23. A cell according to claim 22 which harbours a construct as defined in WO 01/09342 PCT/GB00/02924 -39 part (a) of claim 15 and which is capable of expressing a functional ecdysone receptor.
24. A cell according to claim 23, wherein the functional ecdysone 5 receptor comprises a heterodimer of the ecdysone receptor (EcR) or functional variant thereof and the human retinoid X receptor (RXR) or functional variant thereof.
25. A cell according to claim 22 which harbours a construct as defined in 10 part (b) of claim 15 and which is capable of expressing the tetracycline repressor protein or a functional variant thereof.
26. A process for preparing microcapsules comprising encapsulating cells according to any one of claims 22 to 25.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9918076.2A GB9918076D0 (en) | 1999-07-30 | 1999-07-30 | Microencapsulated nitric oxide synthase source |
GB9918076 | 1999-07-30 | ||
GB0016172A GB0016172D0 (en) | 2000-06-30 | 2000-06-30 | Microencapsulated nitric oxide synthase source |
GB0016172 | 2000-06-30 | ||
PCT/GB2000/002924 WO2001009342A1 (en) | 1999-07-30 | 2000-07-28 | Microencapsulated nitric oxide synthase source |
Publications (1)
Publication Number | Publication Date |
---|---|
AU6174500A true AU6174500A (en) | 2001-02-19 |
Family
ID=26244581
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU61745/00A Abandoned AU6174500A (en) | 1999-07-30 | 2000-07-28 | Microencapsulated nitric oxide synthase source |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1203084A1 (en) |
JP (1) | JP2003506047A (en) |
AU (1) | AU6174500A (en) |
CA (1) | CA2380787A1 (en) |
WO (1) | WO2001009342A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115487779A (en) * | 2022-06-01 | 2022-12-20 | 同济大学 | Preparation method of ferrous ion/cellulose nanocrystal/sodium alginate composite material and application of composite material in adsorption of tetracycline |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT105489B (en) * | 2011-01-18 | 2014-05-13 | Ass For The Advancement Of Tissue Engineering And Cell Based Technologies & Therapies A4Tec | DEVICE, METHOD AND SYSTEM OF MANUFACTURE OF MICROCAPSULES |
US9555007B2 (en) | 2013-03-14 | 2017-01-31 | Massachusetts Institute Of Technology | Multi-layer hydrogel capsules for encapsulation of cells and cell aggregates |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5800829A (en) * | 1991-04-25 | 1998-09-01 | Brown University Research Foundation | Methods for coextruding immunoisolatory implantable vehicles with a biocompatible jacket and a biocompatible matrix core |
US5658565A (en) * | 1994-06-24 | 1997-08-19 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Inducible nitric oxide synthase gene for treatment of disease |
US5972650A (en) * | 1997-06-26 | 1999-10-26 | Brigham And Women's Hospital | Tetracycline repressor regulated mammalian cell transcription and viral replication switch |
US6333318B1 (en) * | 1998-05-14 | 2001-12-25 | The Salk Institute For Biological Studies | Formulations useful for modulating expression of exogenous genes in mammalian systems, and products related thereto |
-
2000
- 2000-07-28 AU AU61745/00A patent/AU6174500A/en not_active Abandoned
- 2000-07-28 CA CA002380787A patent/CA2380787A1/en not_active Abandoned
- 2000-07-28 WO PCT/GB2000/002924 patent/WO2001009342A1/en not_active Application Discontinuation
- 2000-07-28 EP EP00948182A patent/EP1203084A1/en not_active Withdrawn
- 2000-07-28 JP JP2001514134A patent/JP2003506047A/en active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115487779A (en) * | 2022-06-01 | 2022-12-20 | 同济大学 | Preparation method of ferrous ion/cellulose nanocrystal/sodium alginate composite material and application of composite material in adsorption of tetracycline |
Also Published As
Publication number | Publication date |
---|---|
CA2380787A1 (en) | 2001-02-08 |
JP2003506047A (en) | 2003-02-18 |
WO2001009342A1 (en) | 2001-02-08 |
EP1203084A1 (en) | 2002-05-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Al-Hendy et al. | Correction of the growth defect in dwarf mice with nonautologous microencapsulated myoblasts—an alternate approach to somatic gene therapy | |
US6027721A (en) | Device and method for encapsulated gene therapy | |
US20050289658A1 (en) | System for regulating in vivo the expression of a transgene by conditional inhibition | |
Serguera et al. | Control of erythropoietin secretion by doxycycline or mifepristone in mice bearing polymer-encapsulated engineered cells | |
JP2005239726A (en) | Method for implanting encapsulated cell into host | |
JP2003517863A (en) | Surgical needle with leaching tip and use thereof | |
CN101883777A (en) | The antisense that fibroblast growth factor acceptor 4 is expressed is regulated | |
Mitanchez et al. | Glucose-stimulated genes and prospects of gene therapy for type I diabetes | |
DE69927249T2 (en) | INDUCING ALPHAVIRENGEN EXPRESSION SYSTEM | |
CN103638002B (en) | The liver cell composition of packing | |
KR19990022414A (en) | Cell line producing pain compounds for pain treatment | |
JPH0235091A (en) | Control of manifestation in mammal cell | |
EP1534832A2 (en) | Compositions and methods for tissue specific or inducible inhibition of gene expression | |
AU2006279395A1 (en) | Ocular gene therapy using avalanche-mediated transfection | |
AU6174500A (en) | Microencapsulated nitric oxide synthase source | |
Basic et al. | Microencapsulation and transplantation of genetically engineered cells: a new approach to somatic gene therapy | |
ES2304444T3 (en) | USEFUL NUCLEIC ACID CONSTRUCTIONS FOR THE REGULATED GLUCOSE PRODUCTION OF HUMAN INSULIN IN THE SOMATIC CELLULAR STRETCHES. | |
Efron et al. | A novel method of studying wound healing | |
US6106827A (en) | Method of producing genetically modified astrocytes and uses thereof | |
US6743780B1 (en) | Plasmid stabilization | |
AU724537B2 (en) | Method for gene transfer to the central nervous system | |
US20030004125A1 (en) | Inducible gene | |
CN114507695B (en) | Recombinant vector and method for regulating neuron activity | |
AU765149B2 (en) | Method for gene transfer to the central nervous system | |
Jiang et al. | 641. Gene Therapy for Type II Diabetes by Adeno-Assoicated Viral-Mediated Gene Transfer of AntiGFAT1 |